BioSpace News Archive

Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers

A sterilant is a sterilizing agent used by the medical industry to inactivate or destroy various types of microorganisms present in surgical instruments and medical supplies.

The growing prevalence of eye disorders worldwide is a prime factor augmenting the growth of the global ophthalmic Photocoagulator market.

Geneva, Switzerland, September8, 2021 - Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that CEO, Tim Dyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

ICU Medical, Inc. and Smiths Group plc announced that ICU Medical has committed1 to acquire the Smiths Medical division in a transaction that is superior to the existing proposed sale of Smiths Medical to Trulli Bidco Limited.

Ixaka Ltd, an integrated cell and gene therapy company, announces positive interim results of its lead REX-001 drug candidate from a Phase 3 clinical trial, which evaluated the safety and efficacy results 12 months after treatment with REX-001 or placebo in patients diagnosed with chronic limb-threatening ischemia and diabetes.

Sensorion a pioneering clinical-stage biotechnology, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, and Cochlear Limited, the global leader in implantable hearing solutions, announce the initiation of a pilot study of the first-in-class small molecule drug SENS-401 in patients scheduled for cochlear implantation.

In2Bones Global, Inc. announces the U.S. launch of its CoLink® Mfx Midfoot Plating System.

Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported recent pipeline and business highlights and second quarter 2021 financial results.

ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat autoimmune and inflammatory disorders and other diseases, using self-replicating RNA (srRNA).